Cytoplasmic expression of oestrogen receptor beta (ERβ) as a prognostic factor in vulvar squamous cell carcinoma in elderly women

Histopathology

Volumn 59, Issue 5, 2011, Pages 909-917

  Zannoni, Gian F ^a   Prisco, Maria G ^a   Vellone, Valerio G ^a   de Stefano, Ilaria ^a   Vizzielli, Giuseppe ^a   Tortorella, Lucia ^a   Fagotti, Anna ^a   Scambia, Giovanni ^a   Gallo, Daniela ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Ki67; Oestrogen receptor beta; P21; Prognosis; Vulvar cancer

Indexed keywords

ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; VULVA CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYTOPLASM; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VULVAR NEOPLASMS;

HUMAN PAPILLOMAVIRUS; ORYCTOLAGUS CUNICULUS;

EID: 81555214742     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04029.x     Document Type: Article

References (40)

1. American Cancer Society. Cancer facts and figures 2009. Atlanta, GA: American Cancer Society, 2009.
2. Horner MJ, Ries LAG, Krapcho M et al. eds. SEER cancer statistics review, 1975-2006. Bethesda, MD: National Cancer Institute. Available at:, based on November 2008 SEER data submission, posted to the SEER website, 2009 (last accessed August 2010).
3. Bodelon C, Madeleine MM, Voigt LF, Weiss NS. Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control 2009; 20; 1779-1782.
4. Canavan TP, Cohen D. Vulvar cancer. Am. Fam. Physician 2002; 66; 1269-1274.
5. Stroup AM, Harlan LC, Trimble EL. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol. Oncol. 2008; 108; 577-583.
6. Dolan JR, McCall AR, Gooneratne S, Walter S, Lansky DM. DNA ploidy, proliferation index, grade, and stage as prognostic factors for vulvar squamous cell carcinomas. Gynecol. Oncol. 1993; 48; 232-235.
7. Smyczek-Gargya B, Volz B, Geppert M, Dietl J. A multivariate analysis of clinical and morphological prognostic factors in squamous cell carcinoma of the vulva. Gynecol. Obstet. Invest. 1997; 43; 261-267.
8. Rhodes CA, Cummins C, Shafi MI. The management of squamous cell vulval cancer: a population based retrospective study of 411 cases. Br. J. Obstet. Gynaecol. 1998; 105; 200-205.
9. Rouzier R, Haddad B, Plantier F, Dubois P, Pelisse M, Paniel BJ. Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet. Gynecol. 2002; 100; 1159-1167.
10. Raspagliesi F, Hanozet F, Ditto A et al. Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. Gynecol. Oncol. 2006; 102; 333-337.
11. Homesley HD, Bundy BN, Sedlis A et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am. J. Obstet. Gynecol. 1991; 164; 997-1003.
12. Knopp S, Tropè C, Nesland JM, Holm R. A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice [Review]. J. Clin. Pathol. 2009; 62; 212-218.
13. Zannoni GF, Prisco MG, Vellone VG, De Stefano I, Scambia G, Gallo D. Changes in the expression of oestrogen receptors and E-cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma: a pilot study. Histopathology 2011; 58; 265-275.
14. Mosny DS, Brito F, Bender HG. Immunohistochemical investigations of estrogen receptors in normal and neoplastic squamous epithelium of the vulva. J. Reprod. Med. 1990; 35; 1005-1007.
15. Kabulski Z, Frankman O. Histologic malignancy grading in invasive squamous cell carcinoma of the vulva. Int. J. Gynaecol. Obstet. 19781979; 16; 233-237.
16. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 2009; 105; 103-104.
17. Hayat MA. Estrogens. In Microscopy, immunohistochemistry, and antigen retrieval methods for light and electron microscopy. New York, NY: Kluwer Academic/Plenum Publishers, 2002; 276-277.
18. Gallo D, Zannoni GF, Martinelli E et al. Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland. Menopause 2006; 13; 72-79.
19. Shaaban AM, Green AR, Karthik S et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin. Cancer Res. 2008; 14; 5228-5235.
20. Zhang G, Liu X, Farkas AM et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol. Endocrinol. 2009; 23; 146-156.
21. Pietras RJ, Márquez-Garbán DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin. Cancer Res. 2007; 13; 4672-4676.
22. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl. Recept. Signal. 2008; 6; e003.
23. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004; 64; 423-428.
24. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl Acad. Sci. USA 2004; 101; 1566-1571.
25. Pravettoni A, Mornati O, Martini PG et al. Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Mol. Cell. Endocrinol. 2007; 263; 46-54.
26. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J. Endocrinol. 2007; 193; 421-433.
27. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009; 9; 400-414.
28. Gartel AL. p21(WAF1/CIP1) and cancer: a shifting paradigm? Biofactors 2009; 35; 161-164.
29. Knopp S, Bjørge T, Nesland JM, Tropé C, Scheistrøen M, Holm R. p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas. Gynecol. Oncol. 2004; 95; 37-45.
30. Hendricks JB, Wilkinson EJ, Kubilis P, Drew P, Blaydes SM, Munakata S. Ki-67 expression in vulvar carcinoma. Int. J. Gynecol. Pathol. 1994; 13; 205-210.
31. Hantschmann P, Lampe B, Beysiegel S, Kurzl R. Tumor proliferation in squamous cell carcinoma of the vulva. Int. J. Gynecol. Pathol. 2000; 19; 361-368.
32. Chan JK, Sugiyama V, Pham H et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol. Oncol. 2007; 104; 636-641.
33. Burger MP, Hollema H, Emanuels AG, Krans M, Pras E, Bouma J. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol. Oncol. 1995; 57; 327-334.
34. Maggino T, Landoni F, Sartori E et al. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. Cancer 2000; 89; 116-122.
35. Woelber L, Mahner S, Voelker K et al. Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res. 2009; 29; 545-552.
36. Gameiro C, Romao F. Changes in the immune system during menopause and aging [Review]. Front. Biosci. 2010; 2; 1299-1303.
37. Ueda Y, Enomoto T, Kimura T, Yoshino K, Fujita M, Kimura T. Two distinct pathways to development of squamous cell carcinoma of the vulva. J. Skin Cancer 2011; Article ID 951250, 7 pages, 2011. doi: 10.1155/2011/951250.
38. Hacker NF. Revised FIGO staging for carcinoma of the vulva. Int. J. Gynaecol. Obstet. 2009; 105; 105-106.
39. Imamov O, Shim GJ, Warner M, Gustafsson JA. Estrogen receptor beta in health and disease. Biol. Reprod. 2005; 73; 866-871.
40. Blizzard TA. Selective estrogen receptor modulator medicinal chemistry at Merck. A review [Review]. Curr. Top. Med. Chem. 2008; 8; 792-812.